
Director, Regulatory CMC
Immuneering Corporation$235K – $270K per yearUnited States only
Apply now
Opens the original posting.
Apply nowShare job
Copy link or share on social media.
Apply on the original site
Companies in this catalog do not charge applicants. Never send money to apply.
ABOUT IMMUNEERING
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company developing oncology therapies using its proprietary Deep Cyclic Inhibition platform. Our lead asset, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK in active Phase 2 and Phase 3 (MAPKeeper 301) clinical trials in pancreatic cancer and RAS-mutant non-small cell lung cancer, as well as additional solid tumor programs. We are committed to delivering transformative treatments to patients with limited options through rigorous science and a collaborative, mission-driven culture.